Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The CDMO upgrade represents a transformational step for Remedium Lifecare
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Subscribe To Our Newsletter & Stay Updated
